Gilead’s Trodelvy Secures FDA Approval for Expanded Use in Triple-Negative Breast Cancer
Gilead Sciences (NASDAQ:GILD) gained a significant regulatory win on June 25, 2026, when the U.S. Food and Drug Administration approved Trodelvy (sacituzumab govitecan-hziy) for two first-line indications in adults with triple-negative breast cancer (TNBC). The approvals mark a pivotal expansion for the antibody-drug conjugate, which was previously limited to later-line settings.
The first approval covers Trodelvy as a single-agent therapy for patients with unresectable locally advanced or metastatic TNBC who are not candidates for PD-1 or PD-L1 inhibitor-based treatment. The second greenlights Trodelvy in combination with Merck’s Keytruda (pembrolizumab) or the subcutaneous formulation Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) for patients whose tumors express PD-L1 as determined by an FDA-authorized test.
Triple-negative breast cancer, which accounts for roughly 15–20% of all breast cancer cases, lacks the three most common hormone receptors, making it particularly aggressive and difficult to treat. Trodelvy—a Trop-2-directed antibody-drug conjugate engineered to deliver the cytotoxic agent SN-38 directly to cancer cells—has already demonstrated survival benefits in earlier trials. Analysts expect the new frontline approvals to significantly expand the drug’s addressable patient population and reinforce Gilead’s oncology pipeline.
Only days earlier, on June 23, the European Commission granted marketing authorization for Trodelvy as monotherapy in the same first-line metastatic TNBC setting for patients ineligible for PD-1/PD-L1 inhibitors. This makes Trodelvy the first antibody-drug conjugate approved in first-line metastatic TNBC across the European Union’s 27 member states, plus Norway, Iceland, and Liechtenstein—a major step in Gilead’s global strategy.
Separately, Gilead disclosed on June 16 that the FDA had accepted its supplemental New Drug Application for Yeztugo, a once-weekly oral tablet for HIV pre-exposure prophylaxis (PrEP). The FDA set a PDUFA action date of February 2, 2027. If approved, Yeztugo could offer a more convenient alternative to daily PrEP pills, further diversifying Gilead’s HIV prevention portfolio.
The FDA’s latest decision underscores Gilead’s ongoing transition from its core HIV business toward oncology, where Trodelvy remains a cornerstone asset. However, the drug faces competition from other Trop-2-targeting therapies and emerging immunotherapies in the TNBC space. Investors will be watching upcoming sales data and potential label expansions closely.
Beyond the headlines, Gilead Sciences discovers, develops, and commercializes medicines in areas of high unmet medical need across the U.S., Europe, and international markets. The company continues to invest in both its oncology pipeline and its long-standing leadership in HIV.